COR

$334.71

Post-MarketAs of Mar 17, 8:00 PM UTC

Cencora, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$334.71
Potential Upside
11.4%
Whystock Fair Value$372.74
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Distribution

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home hea...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$65.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.13
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Strong income play. Yield provides a meaningful total return floor.
69.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
133.47%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.47

Recent News

Zacks
Mar 17, 2026

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Healthcare Dive
Mar 17, 2026

Cencora CFO announces retirement

James Cleary will step down from the post on June 30, but stay on as an adviser to the company through the end of the year. He’s the second finance chief of a drug distributor to announce their retirement this month.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Investor's Business Daily
Mar 13, 2026

How Cardinal Health, The IBD Stock Of The Day, Is Navigating The Tricky Macro

Cardinal Health is Friday's IBD Stock Of The Day. Shares are in a buy zone as the medical wholesaler easily navigates macro challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Why Is Avantor (AVTR) Down 13.6% Since Last Earnings Report?

Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 13, 2026

CAH's Pharma Segment Gains 19% in Q2'26: Is the Growth Sustainable?

CAH's Pharmaceutical and Specialty Solutions segment surged in fiscal Q2'26 with 19% revenue growth to $61B, fueled by specialty drugs, GLP-1 demand and generics momentum.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.